PRIOR AUTHORIZATION POLICY Oncology (Oral - Bruton's Tyrosine Kinase Inhibitor) - Jaypirca Prior
Prior authorization policy for oral Bruton's tyrosine kinase inhibitor Jaypirca (pirtobrutinib) for prescription benefit coverage under Cigna plans, defining medical necessity criteria for FDA-approved indications and other uses with supportive evidence, duration of approval, and exclusions.
Chronic Lymphocytic Leukemia condition moved from Other Uses to FDA-Approved Uses due to new FDA labeling and criteria updated to require patient has tried at least one BTK inhibitor.
Marginal Zone Lymphoma condition and criteria were added to Other Uses with Supportive Evidence.
Mantle Cell Lymphoma requirement clarified to 'chemotherapy regimen' and removed language specifying frailty example.
Richter's Transformation criteria updated to include option for patient currently receiving at least one chemotherapy regimen.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.